Compare · BCEL vs LLY
BCEL vs LLY
Side-by-side comparison of Atreca Inc. (BCEL) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BCEL and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $234.46B, about 3448.7x BCEL ($68.0M).
- LLY has hit the wire 10 times in the past 4 weeks while BCEL has been quiet.
- LLY has more recent analyst coverage (25 ratings vs 1 for BCEL).
- Company
- Atreca Inc.
- Eli Lilly and Company
- Price
- $0.18+0.40%
- $884.02-3.63%
- Market cap
- $68.0M
- $234.46B
- 1M return
- -
- -3.48%
- 1Y return
- -
- +0.77%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 0
- 10
- Recent ratings
- 1
- 25
Atreca Inc.
Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology. Atreca, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest BCEL
- SEC Form DEFM14A filed by Atreca Inc.
- Orwin John A bought $0 worth of Series A Junior Preferred Stock (1 units at $0.01) (SEC Form 4)
- SEC Form PREM14A filed by Atreca Inc.
- Serafini Tito sold $1,455 worth of shares (20,788 units at $0.07), decreasing direct ownership by 32% to 43,636 units (SEC Form 4)
- Orwin John A sold $8,597 worth of shares (22,951 units at $0.37), decreasing direct ownership by 23% to 77,541 units (SEC Form 4)
- Serafini Tito sold $3,144 worth of shares (8,393 units at $0.37), decreasing direct ownership by 12% to 64,424 units (SEC Form 4)
- Courtney Phillips sold $2,645 worth of shares (7,061 units at $0.37), decreasing direct ownership by 12% to 50,431 units (SEC Form 4)
- SEC Form 15-12G filed by Atreca Inc.
- SEC Form S-8 POS filed by Atreca Inc.
- SEC Form S-8 POS filed by Atreca Inc.
Latest LLY
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 4 filed by Sulzberger Gabrielle
- SEC Form 4 filed by Luciano Juan R
- SEC Form 4 filed by Fyrwald J Erik
- SEC Form 4 filed by Alvarez Ralph
- Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
- Lilly confirms date and conference call for first-quarter 2026 financial results announcement
- ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
- Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
- Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.